BioCryst Prices Offering At $5.15/Share

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) has offered to sell 15.53 million shares of its common stock to the public at a price of $5.15 each. The underwriter has a 30-day option to purchase up to an additional 2.33 million shares of its common stock.

The offering is expected to rake in gross proceeds of $80 million, and is scheduled to close on or about September 15, 2017.

BioCryst expects to use this offering net proceeds for general corporate purposes, including funding the global launch preparation of BCX7353.

On September 5, 2017, BioCryst reported positive results from its APeX-1 Phase 2 Trial on BCX7353 in hereditary angioedema. BioCryst intends to meet with FDA and EMA during the fourth quarter of 2017 to finalize the Phase 3 program.

BCRX closed Tuesday's trading session at $5.23.